EIP is delighted to announce a NEW free-to-access webinar on Spotting the Signs of Mucopolysaccharidosis (MPS)  
     
 

SES-S4-M4: MPS Case Studies - Practical Examples of an Effective Identification and Referral Process

 
     
 

20 April 2022 

 
 

The webinar is now organised. Register to access the video. 

 
  Can't attend the live event? By registering, you will receive a link to the on-demand version after the session concludes.   
     
 

COURSE DESCRIPTION

 
  Misdiagnosis of Mucopolysaccharidosis (MPS) results in late diagnosis and the late start of treatment, which has significant consequences on long-term outcomes. This gap usually results in confusing symptoms with other conditions, most notably trying to address symptoms directly and therefore delaying actual diagnosis and treatment, or referring the patient to the wrong pediatric specialties causing further delays in the condition’s management chain.  
     
  Language: English ● Duration: 30 minutes followed by questions from the audience  
     
  Presenter: Roberto Giugliani, Professor of Medical Genetics, Federal University of Rio Grande do Sul, Brazil  
     
 

TARGET AUDIENCE

 
  This educational activity is designed for an international audience of General Pediatricians, General Practitioners, Pediatric Endocrinologists, Pediatric Rheumatologists and other physicians and healthcare professionals with an interest in Metabolic Diseases.  
     
     
         
 

LEARNING OBJECTIVES

 
  ✓ Reviewing a number of case studies demonstrating the importance of suspecting and detecting MPS through the various signs  
     
  ✓ Examining the multi-systemic features of the diseases through cases   
     
  ✓ Know what are the musculoskeletal manifestations of mucopolysaccharidoses   
     
  ✓ Understanding the latest treatment options available to the patient  
     
         
         
 

Click below to start your free registration

 
         
   

 

The Spot the Early Signs program aims to fight under-diagnosed or late-diagnosed conditions for which treatments are available and where early detection and early treatment could make a significant difference in the condition's development, the quality of life and the survival of patients.